Literature DB >> 18831305

The immunocompromised adult patient and surgery.

Keith E Littlewood1.   

Abstract

The perioperative management of immunosuppressed patients remains relatively unsophisticated. Rational management involves understanding the normal immune response to injury as modified by the preexisting or imposed abnormalities that immunosuppressed patients manifest on the basis of their disease and/or treatment. Patients with cancer, infected with human immunodeficiency virus, and having had an organ transplant are extreme examples of disordered immunity and it is important to understand the effects of their diseases and treatments. In the future, however, more appropriate management will require anticipation and appreciation of frequent preoperative immunotherapy, a more complete understanding of the immunological response to anesthesia and surgery, the ability to assess immune reserve and stratify risk within the context of that profile, and a better knowledge of the immunological effect of anesthetic agents.

Entities:  

Mesh:

Year:  2008        PMID: 18831305     DOI: 10.1016/j.bpa.2008.05.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  4 in total

1.  [Perioperative management of long-term medication].

Authors:  I Vogel Kahmann; W Ruppen; G Lurati Buse; D A Tsakiris; M Bruggisser
Journal:  Internist (Berl)       Date:  2011-01       Impact factor: 0.743

2.  Copper and anesthesia: clinical relevance and management of copper related disorders.

Authors:  Adrian Langley; Charles T Dameron
Journal:  Anesthesiol Res Pract       Date:  2013-05-13

3.  Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.

Authors:  Michael D Tarantino; Kalpana K Bakshi; Andrés Brainsky
Journal:  Platelets       Date:  2013-02-12       Impact factor: 3.862

4.  Intraoperative Acute Respiratory Failure in an Immunocompromised Patient with Human Metapneumovirus.

Authors:  Justin S Merkow; Erik J Nelson
Journal:  Am J Case Rep       Date:  2018-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.